VLA-4 inhibitory drug

US8129366B2 · kind B2 · utility

Assignee

• DAIICHI SANKYO COMPANY, LIMITED · JP

Inventors

• Nobuo Machinaga · Tokyo, JP
• Shin Iimura · Tokyo, JP
• Yoshiyuki Yoneda · Edogawa, JP
• Jun Chiba · Tokyo, JP
• Fumihito Muro · Edogawa, JP
• Hideko Hoh · Edogawa, JP
• Atsushi Nakayama · Tokyo, JP

Key dates

• Filing date: Dec 13, 2006
• Grant date: Mar 6, 2012
• Expiry date: Dec 11, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D495/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

There is provided a VLA-4 inhibitory drug having good oral absorbability and exhibiting sufficient anti-inflammatory effects when administered orally.A compound represented by the following formula (I):wherein R1 represents a hydrogen atom or a C1-8 alkyl group; R2 represents a hydrogen atom, a halogen atom, a C1-8 alkoxy group, or a benzyloxy group which may be substituted; Q represents a monocyclic or bicyclic nitrogen-containing heterocyclic group which may be substituted, and has a nitrogen atom as the bonding site; Y represents an oxygen atom or CH2; W represents a bicyclic aromatic hydrocarbon ring group which may be substituted, or a bicyclic aromatic heterocyclic group which may be substituted; R3a, R3b and R3c each independently represent a hydrogen atom, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group; and A1 represents a nitrogen atom or C—R3d (wherein R3d represents a hydrogen atom, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group),